Hepatic dysfunction following hematopoietic stem cell transplantation (HSCT) is common, but making the correct diagnosis can be challenging. Liver biopsies can serve as an important diagnostic tool when the etiology cannot be clearly determined by laboratory data, physical examination, and imaging studies. We reviewed 12 consecutive pediatric patients (seven males, five females, age 9-23 years) who received allogeneic HSCT and underwent a laparoscopicguided liver biopsy for hepatic dysfunction of unknown etiology from 1998 to 2005. Biopsies were performed using a single-port technique with a 16 or 18 gauge, spring-loaded biopsy gun. The time from HSCT to biopsy ranged from 31 days to 821 days (median 92 days). No intra-or postoperative complications were observed. The initial clinical diagnosis was confirmed in seven patients, whereas the initial working diagnosis was inaccurate in the remaining five patients. Our results suggest that laparoscopic-guided liver biopsy is an informative and safe procedure in pediatric HSCT recipients; this approach helped delineate the true cause of hepatic dysfunction and changed our therapeutic approach in approximately 40% of the patients reviewed. While the safety record at our institution appears promising, a larger multi-institutional study would be necessary to more accurately describe the overall efficacy of this procedure in pediatric HSCT patients. Bone Marrow Transplantation (2005) 36, 891-896.
Hepatic dysfunction is a significant complication following hematopoietic stem cell transplant (HSCT) and has been reported to occur more commonly than clinically suspected. 1, 2 Moreover, the management of hepatic dysfunction in this setting can be complex since overlapping patterns of disease often complicate the diagnosis, but establishing the correct diagnosis is crucial since the institution of disease-specific therapy can have significant consequences with respect to the patient's overall outcome.
When the etiology of hepatic dysfunction following HSCT is unclear, histologic examination of the liver is desirable so that appropriate treatment can be administered and unnecessary and potentially harmful therapy can be avoided. Thus, liver biopsy can be an important diagnostic tool in this context. 3 Standard procedures for obtaining hepatic tissue for histologic assessment include percutaneous and transjugular (venous) approaches. Percutaneous liver biopsies are associated with both inadequate tissue sampling and hemorrhagic complications, [4] [5] [6] and the risk of bleeding in these patients is often compounded by the coagulopathic state that often accompanies the concurrent liver disease. Transjugular liver biopsies are typically performed in patients with contraindications to the percutaneous approach. 7 Despite the reported safety and effectiveness of this approach in many large patient series, [8] [9] [10] [11] the risk of hemorrhage can be as high as 20% 9, 12 and the use of this approach in children can be technically challenging. At our institution, the standard of care in approaching the work-up of hepatic dysfunction of unclear etiology following HSCT is to perform a laparoscopic-guided liver biopsy. In recent years, this approach has emerged as a safe and well-tolerated procedure for evaluating both adults and children with liver disease; 13, 14 however, little data exist regarding the feasibility of this technique in pediatric patients who have undergone HSCT. The aim of this paper is to report on the safety and effectiveness of the laparoscopic approach in pediatric HSCT patients using a Monopty Biopsy instrument.
Patients and methods

Study population
Information pertaining to physical examinations, medication profiles, noninvasive radiologic studies and laboratory analysis including but not limited to complete blood counts with differential, hepatic function profiles and coagulation studies was obtained after receiving approval from the Institutional Review Board at the University of Michigan. In all, 12 consecutive pediatric patients who had undergone allogeneic HSCT between 1998 and 2005 and subsequently underwent a laparoscopic liver biopsy procedure were included in this retrospective study. Laparoscopic biopsies were performed in these patients because (1) all exhibited evidence of hepatic injury that persisted despite empiric medical management, and (2) noninvasive techniques such as ultrasonography, plain radiographs, and computed tomography scans failed to define the specific etiology of the hepatocellular toxicity.
Hematopoietic stem cell transplantation procedure
Four patients received HSCT from their HLA identical sibling; five patients received HSCT from matched unrelated donors, one patient received a T cell-depleted matched unrelated HSCT, one patient received a mismatched unrelated HSCT, and one patient received a mismatched cord blood transplant from a sibling ( Table 1) . Conditioning regimens included fludarabine, busulfan and cyclophosphamide (patient #1); cyclophosphamide, antithymocyte globulin and total body irradiation (patient #2); busulfan and cyclophosphamide (patient #3), cyclophosphamide and total body irradiation (patient #4), etoposide, cyclophosphamide and total body irradiation (patient #5); busulfan, cytosine arabinoside and cyclophosphamide (patients #6-11); and fludarabine, busulfan and total lymphoid irradiation (patient #12). Acute graftversus-host disease (GVHD) prophylaxis included cyclosporine and mycophenolate for patient #1, cyclosporine and methylprednisolone for patient #2, tacrolimus and short-course methotrexate for patients #3-11, and mycophenolate, tacrolimus, and short-course methotrexate for patient #12. Infectious prophylaxis included sulfamethoxazole and trimethroprim, fluconazole, norfloxacin, and acyclovir as per the University of Michigan Blood and Marrow Transplantation Program Standard of Care Guidelines (www.med.umich.edu/i/cancer/bmtsoc.htm). Granulocytecolony stimulating factor (Neupogen, AMGEN) was administered to all patients starting on day 6 following HSCT.
Laparoscopic biopsy procedure
Laparoscopic liver biopsies were performed using a singleport technique with a 5-mm port placed in the umbilicus for camera access. A 5-mm, 301-angled laparoscope was then introduced. In each case, the entire peritoneal surface, including the liver and spleen was inspected allowing for the assessment of both diffuse and localized pathology that might be confined to specific lobar segments. A small (2 mm) stab wound was then made in the right upper quadrant through which a 16 or 18 gauge spring loaded biopsy gun (Monopty Biopsy instrument, CR Bard Inc., Covington, GA, USA) was passed and then directed to the right lobe of the liver. A needle was subsequently placed in the area where the maximal thickness of the liver in the anterior-posterior dimension was determined to be and fired. This process was usually repeated for a total of four to five passes, each pass generating a separate core of liver tissue. The liver parenchyma was then observed closely for signs of bleeding. Before removing the camera, the abdominal pressure was dropped from 12-15 to 6-8 mmHg and the biopsy sites examined. In most cases, the needle point electrocautery was used through the stab wound incision and the sites were coagulated, controlling any bleeding. The specimens were subsequently sent fresh to surgical pathology for processing and review.
Results
Patient characteristics, including age, gender, initial diagnosis, histologic, and laboratory findings, and post-biopsy results are summarized in Table 1 . The median age of the patients was 17 years (range 9-23 years). There were seven male patients and five female patients. The time from HSCT to laparoscopic-guided liver biopsy ranged from 31 days to 821 days (median 92 days). Laboratory abnormalities noted prior to the biopsy included elevated total bilirubin (median 8.5 g/dl, range 1.2-22.2), conjugated bilirubin (median 5.7 g/dl, range 0-18.1) and alkaline phosphatase (median 222 U/l, range 74-1060). Median values (and ranges) for other laboratory results included AST 117 U/l (32-419), ALT 184 U/l (32-738), unconjugated bilirubin 0.7 g/dl (0.1-1.7), platelet count 48 000/ mm 3 (19 000-411 000), PT 10.8 s (8.8-12.7) and PTT 26.7 s (18.7-38.6). As shown in Table 1 , nine of 12 (75%) patients had platelet counts less than 100 000/mm 3 , seven of 12 (58%) less than 50 000/mm 3 , and four of 12 (33%) patients had absolute neutrophil counts less than 1500/mm 3 . Platelet transfusions were administered to nine patients on the day of the procedure and also on the first postoperative day as needed. In addition, three patients required fresh frozen plasma within 7 days of the procedure to correct PTT abnormalities.
No intra-or post-operative complications were reported in our series of patients. The initial clinical diagnosis of liver injury was confirmed in seven patients (Table 1) . Four patients had cholestatic liver biopsies with bile duct damage, lymphocytic cholangitis, and apoptosis, features consistent with GVHD ( Figure 1b ; normal tissue shown for comparison in Figure 1a) . Each of the four patients was subsequently treated with appropriate immunosuppressive therapy, showed significant improvement with resolution of elevated transaminases and bilirubin, and remains alive. The differential diagnosis considered in patient #4 included total parenteral nutrition (TPN) cholestasis, infectious hepatitis, and GVHD. Histologic examination of the liver revealed diffuse damage of the bile ducts, endophlebitis, and cholestatic changes consistent with a hepatic GVHD. In patients #8 and 11, the clinical suspicion of veno- occlusive disease (VOD) was confirmed by the finding of hemorrhagic central zone necrosis and occluded central veins (Figure 1c ). Patient #11 remains alive, but patient #8 died from multisystem organ failure (MSOF). In the remaining five patients, results of the laparoscopicguided liver biopsy demonstrated that the working diagnosis was inaccurate. In four of these five patients, the initial etiology for the liver dysfunction was attributed to GVHD. However, histologic examination revealed that the actual causes of hepatic dysfunction were iron overload (patient #1; Figure 1d ), cholestatic liver disease of unclear etiology (patient #2), VOD (patient #3), and hepatocyte injury secondary to drug toxicity or infection (patient #9). Patient #7 presented 815 days following his HSCT with recurrent leukemia and elevated transaminases, and hepatomegaly. Recent travel to South America placed an infectious etiology high on the differential, but tissue analysis revealed massive iron overload, most likely secondary to multiple red cell transfusions. In each case where microscopic examination of liver tissue identified the correct etiology, the appropriate medical intervention was undertaken after the histologic diagnosis was established. Despite these efforts, four of these five patients died at a median of 43 days (range 4-207 days) following the laparoscopic-guided liver biopsy. The causes of death for these patients are summarized in Table 2 and included progressive leukemia, disseminated CMV infection, bacterial sepsis, and MSOF. There was no evidence that the deaths noted in these five patients were related to the procedure itself since none of the patients developed bleeding or other surgically related complications during or following laparoscopy and biopsy. 
Discussion
There are many possible causes for hepatobiliary abnormalities following HSCT. Liver injury in the early posttransplant period (days 0-100) can be secondary to drug toxicity, VOD, acute GVHD, opportunistic (bacterial, viral and fungal) infections, TPN, and acalculous cholecystitis. Causes of liver dysfunction in the late post-transplant period (4100 days) include viral hepatitis, chronic GVHD, and iron overload. 15, 16 In light of the myriad of possible etiologies, establishing the correct diagnosis is essential since the institution of appropriate therapy can have a significant impact on the patient's outcome. Our data reveal that the initial clinical diagnosis was confirmed in just over half of the patients and therefore emphasize the difficulties encountered in diagnosing the cause of liver injury following allogeneic HSCT based upon laboratory data, physical examination, and imaging studies alone.
When the etiology of hepatic dysfunction is unclear, an accurate diagnosis often depends on histological examination of a tissue specimen. Hepatic tissue is often obtained by either transjugular or percutaneous biopsy of the liver, but each of these procedures is associated with significant risks in the post-HSCT setting. For example, bleeding is a major complication following conventional percutaneous liver biopsy, particularly when patients are thrombocytopenic or coagulopathic. 17, 18 In a retrospective analysis of 87 patients who had undergone allogeneic BMT, three out of 13 patients with platelet counts less than 60 000/mm 3 suffered from a fatal hemorrhage. Two of the three patients who bled had an additional complicating factor, one with disseminated intravascular coagulopathy and the other with a small liver laceration. 5 By contrast, procurement of liver tissue via a transjugular approach, in which access to the liver is obtained via the hepatic vein, is associated with a reduced risk of bleeding. 9, 19, 20 The transjugular approach offers other advantages as well, including the ability to perform imaging studies of the hepatic venous system and determining intrahepatic pressures. 9, 12, 21 While this procedure has been used to evaluate hepatic dysfunction in adult HSCT patients, studies in pediatric HSCT recipients are limited. Of the five studies reporting on the success of this approach in children, [22] [23] [24] [25] [26] only two included HSCT patients. 23, 25 These studies concluded that the transjugular liver biopsies are safe and effective in the pediatric population, but this approach also has significant disadvantages including the need for highly skilled personnel, increased procedure time, and concerns relative to inadequate sample size for histologic examination.
12
Laparoscopy is a widely used diagnostic and therapeutic tool, and liver biopsy using this approach has proven to be an effective means for evaluating hepatic dysfunction in adult patients with hematologic malignancies. Iqbal et al 27 reported on a series of 29 adults who were immunocompromised, thrombocytopenic, and often neutropenic following intensive cytotoxic therapy with or without HSCT. In this study, all biopsies were informative, and no complications related to the procedure were reported. The largest series of children evaluated by laparoscopyguided biopsy for the diagnosis of chronic liver disease was reported from the University of Naples in Italy. 13 This series reviewed 80 cases and reported successful results with the laparoscopic technique. The median age of the patients was 6 years (range 50 days to 16 years). Blind percutaneous liver biopsy was contraindicated in 65 children due to underlying thrombocytopenia or coagulation abnormalities. The other 15 children had previously undergone a percutaneous needle biopsy that was not informative due to inadequate tissue sampling.
While the laparoscopic approach appears to be a promising method for obtaining adequate tissue samples in children, little has been reported on how well this technique can be used to evaluate hepatic disease in pediatric patients following HSCT. At our institution, laparoscopic-guided liver biopsy is the preferred technique for this patient population. Laparoscopy offers the benefits of minimal invasiveness with superior visualization of the entire liver and peritoneal cavity. Thus, directed biopsies that result in evaluable tissue specimens are regularly obtained. The laparoscopic technique is superior to open biopsy procedures with respect to cosmetic outcomes and postsurgical recovery time, 27 and maintains hemostatic and tissue procurement advantages over percutaneous and vascular biopsies.
In conclusion, our results suggest that laparoscopicguided liver biopsies in pediatric patients experiencing liver dysfunction following HSCT is a safe and potentially effective diagnostic tool in this setting; all 12 laparoscopic biopsies were informative and no complications were reported as a result of this procedure despite varying degrees of immunosuppression, thrombocytopenia, and neutropenia. Furthermore, a laparoscopic liver biopsy can help to delineate the true cause of a patient's hepatic abnormality and thereby potentially maximize the success of subsequent therapeutic interventions and minimize the adverse affects of misguided treatments. However, a large multi-institutional trial would be necessary to more accurately describe the overall efficacy of this procedure with respect to improving outcomes in pediatric HSCT patients.
